GlassScriptPhysician profile
Victor Vigil
NPI 1972566404
$3,194.59
in general payments reported to CMS, 2019-2025
24 companies · $471 in 2025
The $471 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $60.43 · 2021: $365 · 2022: $468 · 2023: $627 · 2024: $968 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315 · Long Term Medical Supply Or Device Loan: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.35 |
| Long Term Medical Supply Or Device Loan | $749.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,390.00 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $422.65 | 2019-2025 | Enhertu, Lynparza |
| Gilead Sciences, INC. | $323.79 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $217.17 | 2019-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Daiichi Sankyo INC. | $144.19 | 2023-2025 | Enhertu |
| Lilly USA, LLC | $117.21 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Amgen INC. | $89.51 | 2019-2020 | |
| Pfizer INC. | $74.60 | 2019-2024 | |
| Eisai INC. | $57.31 | 2019-2022 | |
| Foundation Medicine, INC. | $47.57 | 2023 | Foundationone Cdx |
| Beigene USA, INC. | $34.56 | 2023-2024 | Brukinsa |
| Astellas Pharma US INC | $29.51 | 2024 | Veozah |
| Pharmaand Gmbh | $26.15 | 2025 | Rubraca |
| Abbvie INC. | $26.01 | 2024 | |
| Janssen Biotech, INC. | $25.71 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $25.65 | 2019-2022 | |
| Tersera Therapeutics LLC | $24.15 | 2023 | Zoladex |
| Beone Medicines USA, INC. | $22.30 | 2025 | Brukinsa |
| Mylan Institutional INC. | $21.84 | 2021 | |
| Baxter Healthcare | $19.28 | 2020 | |
| Spectrum Pharmaceuticals INC. | $15.42 | 2025 | Rolvedon |
| Puma Biotechnology, INC. | $15.03 | 2019 | |
| Celltrion USA INC. | $13.52 | 2024 | Vegzelma |
| E.R. Squibb & Sons, L.L.C. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Vigil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.